Compare UA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | TARS |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | UA | TARS |
|---|---|---|
| Price | $5.98 | $64.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.4M | 497.0K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $55.67 |
| Revenue Next Year | $1.72 | $30.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $3.95 | $38.51 |
| 52 Week High | $7.91 | $85.25 |
| Indicator | UA | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 37.38 |
| Support Level | $5.88 | $61.11 |
| Resistance Level | $6.44 | $67.70 |
| Average True Range (ATR) | 0.26 | 2.45 |
| MACD | -0.11 | -0.98 |
| Stochastic Oscillator | 22.63 | 6.48 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.